Several other analysts also recently issued reports on the company. Zacks Investment Research upgraded ESSA Pharma from a strong sell rating to a hold rating in a research report on Tuesday, July 18th. ValuEngine downgraded ESSA Pharma from a sell rating to a strong sell rating in a research report on Wednesday, June 7th. Finally, Dawson James reiterated a buy rating on shares of ESSA Pharma in a research report on Thursday, August 3rd. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the company’s stock. ESSA Pharma presently has an average rating of Hold and a consensus target price of $4.75.
Shares of ESSA Pharma (EPIX) opened at 0.3046 on Tuesday. ESSA Pharma has a 12 month low of $0.26 and a 12 month high of $2.80. The company’s 50 day moving average price is $0.31 and its 200-day moving average price is $1.97. The firm’s market capitalization is $8.86 million.
ESSA Pharma Company Profile
ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel and proprietary therapies for the treatment of prostate cancer. Its product candidate is EPI-506, an oral small molecule pro-drug that is in Phase 1/2 clinical trial, which blocks the N-terminal domain of the androgen receptor.
Receive News & Ratings for ESSA Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.